Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Loading...
Embargo End Date
ICR Authors
Authors
Collins, DC
Sundar, R
Lim, JSJ
Yap, TA
Sundar, R
Lim, JSJ
Yap, TA
Document Type
Journal Article
Date
2017-01-01
Date Accepted
2016-10-19
Abstract
Precision medicine continues to be the benchmark to which we strive in cancer research. Seeking out actionable aberrations that can be selectively targeted by drug compounds promises to optimize treatment efficacy and minimize toxicity. Utilizing these different targeted agents in combination or in sequence may further delay resistance to treatments and prolong antitumor responses. Remarkable progress in the field of immunotherapy adds another layer of complexity to the management of cancer patients. Corresponding advances in companion biomarker development, novel methods of serial tumor assessments, and innovative trial designs act synergistically to further precision medicine. Ongoing hurdles such as clonal evolution, intra- and intertumor heterogeneity, and varied mechanisms of drug resistance continue to be challenges to overcome. Large-scale data-sharing and collaborative networks using next-generation sequencing (NGS) platforms promise to take us further into the cancer 'ome' than ever before, with the goal of achieving successful precision medicine.
Citation
Trends in pharmacological sciences, 2017, 38 (1), pp. 25 - 40
Source Title
Publisher
CELL PRESS
ISSN
0165-6147
eISSN
1873-3735
Collections
Research Team
Medicine Drug Development Unit (de Bono)